<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00844311</url>
  </required_header>
  <id_info>
    <org_study_id>2008-257</org_study_id>
    <nct_id>NCT00844311</nct_id>
  </id_info>
  <brief_title>Supplementation With Human Chorionic Gonadotropin (hCG) During Controlled Ovarian Stimulation With Recombinant Follicle-stimulating Hormone (FSH) for In Vitro Fertilisation</brief_title>
  <official_title>Supplementation With hCG During Controlled Ovarian Stimulation With Recombinant FSH for in Vitro Fertilisation. A Randomized Controlled Clinical Study. Clinical, Embryological, Endocrine and Genetic Aspects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study whether addition of different doses of human chorionic
      gonadotropins during controlled ovarian stimulation for patients undergoing IVF will improve
      the number of top-quality embryos.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of top-quality embryos at day 3</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implantation rate; Dose of rFSH needed; Serum levels of endocrine parameters; Ongoing pregnancy; Follicular fluid levels of endocrine parameters and cytokines; Expressions of gene families in granulosa cells and the cumulus complex.</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 iu/day of rFSH alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hCG low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 iu/day of rFSH + 50 iu/day of hCG from stimulation day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hCG medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 iu/day of rFSH + 100 iu/day of hCG from stimulation day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hCG high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 iu/day of rFSH + 150 iu/day of hCG from stimulation day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rFSH</intervention_name>
    <description>150 iu/day of rFSH</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>hCG low dose</arm_group_label>
    <arm_group_label>hCG medium dose</arm_group_label>
    <arm_group_label>hCG high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human chorionic gonadotropin</intervention_name>
    <description>50 iu/day of hCG from stimulation day 1</description>
    <arm_group_label>hCG low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human chorionic gonadotropin</intervention_name>
    <description>100 iu/day of hCG from stimulation day 1</description>
    <arm_group_label>hCG medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human chorionic gonadotropin</intervention_name>
    <description>150 iu/day of hCG from stimulation day 1</description>
    <arm_group_label>hCG high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females with indication for COS and IVF;

          2. Age between 25-37 years;

          3. BMI &gt;18 and &lt; 30 kg/m2;

          4. A regular menstrual cycle between 24 and 35 days and presumed to be ovulatory;

          5. Two ovaries;

          6. Tubal or unexplained infertility, including endometriosis stage I/II;

          7. A uterus consistent with expected normal function (e.g. no clinically interfering
             uterine fibroids) documented by transvaginal ultrasound at the screening;

          8. Male partner with sperm quality compatible with fertilization via IVF procedure or
             previous clinical pregnancy;

          9. Early follicular phase serum FSH levels of 1-12 IU/l;

         10. Early follicular phase total antral follicle (2-10mm) count ≥ 6;

         11. Confirmation of down-regulation before randomisation by transvaginal ultrasound;

         12. Willing and able to sign informed consent.

        Exclusion Criteria:

          1. History of or current PCOS, endometriosis stage III/IV or severe male factor requiring
             ICSI;

          2. History of severe ovarian hyperstimulation syndrome (OHSS);

          3. Presence of unilateral or bilateral hydrosalpinx at ultrasound;

          4. More than three previously COS cycles;

          5. Previous poor response on an IVF-cycle, defined as &gt;20 days of gonadotrophin
             stimulation, cancellation due to limited follicular response or less than four
             follicles of ³15 mm diameter;

          6. Previous IVF cycle with unsuccessful fertilization, defined as fertilisation of £20%
             of the retrieved oocytes;

          7. History of recurrent miscarriage;

          8. FSH&gt;12IU/L or LH&gt;12UI/L (early follicular phase);

          9. Contraindications for the use of gonadotropins or GnRH analogues;

         10. Recent history of current epilepsy, HIV infection, diabetes or cardiovascular
             gastrointestinal, hepatic, renal or pulmonary disease;

         11. Pregnancy, lactation or contraindication to pregnancy;

         12. Current past (last 12 months) abuse of alcohol or drugs;

         13. History of chemotherapy (except for gestational conditions) of radiotherapy;

         14. Undiagnosed vaginal bleeding;

         15. Tumours of the ovary, breast, adrenal gland, pituitary or hypothalamus and
             malformation of sexual organs incompatible with pregnancy;

         16. Abnormal karyotyping of the patient (if karyotyping is performed);

         17. Hypersensitivity to any trial product.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Fertility Clinic, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>KBH O</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2009</study_first_submitted>
  <study_first_submitted_qc>February 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2009</study_first_posted>
  <last_update_submitted>August 3, 2010</last_update_submitted>
  <last_update_submitted_qc>August 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2010</last_update_posted>
  <keyword>hCG</keyword>
  <keyword>human chorionic gonadotropin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

